Shares in Sorrento Therapeutics (NSDQ:SRNE) soared today after the company announced that the FDA approved its ZTlido lidocaine pain patch designed to treat patients with post-shingles neuralgia.
The company resubmitted its application for ZTlido to the FDA last year after it was rejected by the U.S. regulatory agency in 2016.
Get the full story at our sister site, Drug Delivery Business News.
The post Sorrento Therapeutics wins FDA nod for post-shingles pain patch appeared first on MassDevice.